BR0206804A - Utilização de (r)-ibuprofeno metanossulfonamida e sais do mesmo no tratamento e prevenção de reações de rejeição a órgãos transplantados - Google Patents

Utilização de (r)-ibuprofeno metanossulfonamida e sais do mesmo no tratamento e prevenção de reações de rejeição a órgãos transplantados

Info

Publication number
BR0206804A
BR0206804A BR0206804-4A BR0206804A BR0206804A BR 0206804 A BR0206804 A BR 0206804A BR 0206804 A BR0206804 A BR 0206804A BR 0206804 A BR0206804 A BR 0206804A
Authority
BR
Brazil
Prior art keywords
prevention
treatment
salts
transplant rejection
organ transplant
Prior art date
Application number
BR0206804-4A
Other languages
English (en)
Inventor
Riccardo Bertini
Francesco Colotta
Roberto Novellini
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of BR0206804A publication Critical patent/BR0206804A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

"UTILIZAçãO DE (R)-IBUPROFENO METANOSSULFONAMIDA E SAIS DO MESMO NO TRATAMENTO E PREVENçãO DE REAçõES DE REJEIçãO A óRGãOS TRANSPLANTADOS". A presente invenção refere-se à utilização de (R)-ibuprofeno metanossulfonamida para a preparação de medicamentos para o tratamento e prevenção de lesão funcional resultante de reações de rejeição de órgãos transplantados. Em particular, é descrita a utilização de sais não-tóxicos de (R)-ibuprofeno metanossulfonamida, tal como o sal de L-lisina, para a prevenção e o tratamento de reações de rejeição de rins transplantados.
BR0206804-4A 2001-02-02 2002-01-30 Utilização de (r)-ibuprofeno metanossulfonamida e sais do mesmo no tratamento e prevenção de reações de rejeição a órgãos transplantados BR0206804A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000206A ITMI20010206A1 (it) 2001-02-02 2001-02-02 Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PCT/EP2002/000946 WO2002062330A2 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs

Publications (1)

Publication Number Publication Date
BR0206804A true BR0206804A (pt) 2004-02-03

Family

ID=11446717

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0206804A BRPI0206804B1 (pt) 2001-02-02 2002-01-30 utilização de (r)-ibuprofeno metanossulfonamida e sais do mesmo no tratamento e prevenção de lesão funcional resultante de reações de rejeição de orgãos transplantados
BR0206804-4A BR0206804A (pt) 2001-02-02 2002-01-30 Utilização de (r)-ibuprofeno metanossulfonamida e sais do mesmo no tratamento e prevenção de reações de rejeição a órgãos transplantados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0206804A BRPI0206804B1 (pt) 2001-02-02 2002-01-30 utilização de (r)-ibuprofeno metanossulfonamida e sais do mesmo no tratamento e prevenção de lesão funcional resultante de reações de rejeição de orgãos transplantados

Country Status (26)

Country Link
US (1) US7560487B2 (pt)
EP (1) EP1355641B1 (pt)
JP (1) JP2004517948A (pt)
KR (1) KR100857898B1 (pt)
CN (1) CN1561205A (pt)
AT (1) ATE304846T1 (pt)
AU (1) AU2002250869B2 (pt)
BR (2) BRPI0206804B1 (pt)
CA (1) CA2432432C (pt)
CZ (1) CZ303665B6 (pt)
DE (1) DE60206245T2 (pt)
DK (1) DK1355641T3 (pt)
EE (1) EE05233B1 (pt)
ES (1) ES2248541T3 (pt)
HU (1) HU229070B1 (pt)
IL (1) IL157180A (pt)
IT (1) ITMI20010206A1 (pt)
MX (1) MXPA03006686A (pt)
NO (1) NO334285B1 (pt)
NZ (1) NZ526655A (pt)
PL (1) PL215109B1 (pt)
PT (1) PT1355641E (pt)
RU (1) RU2257895C2 (pt)
SK (1) SK287632B6 (pt)
WO (1) WO2002062330A2 (pt)
ZA (1) ZA200304861B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004003673T2 (de) * 2004-03-25 2007-10-04 Dompe' Pha.R.Ma S.P.A. Verwendung von N-(2-Aryl-propionyl)-sulfonamiden zur Behandlung von Rückenmarkverletzungen
US8841333B2 (en) 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
WO2008064015A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America Methods for preserving renal function using xanthine oxidoreductase inhibitors
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
US9107912B2 (en) 2010-09-10 2015-08-18 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
AU2018234074B2 (en) * 2017-03-15 2021-06-24 Numares Ag Use of a marker set for determining the risk of kidney rejection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
JPH08231413A (ja) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd 臓器障害に基づく疾患の予防・治療剤
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine

Also Published As

Publication number Publication date
EE200300340A (et) 2003-10-15
RU2003126600A (ru) 2005-02-27
KR100857898B1 (ko) 2008-09-10
CA2432432A1 (en) 2002-08-15
US20040102520A1 (en) 2004-05-27
AU2002250869B2 (en) 2006-10-19
WO2002062330A2 (en) 2002-08-15
SK9732003A3 (en) 2003-11-04
NO20033273D0 (no) 2003-07-18
JP2004517948A (ja) 2004-06-17
IL157180A (en) 2009-06-15
HUP0303024A2 (hu) 2003-12-29
KR20030074725A (ko) 2003-09-19
CZ303665B6 (cs) 2013-02-20
NZ526655A (en) 2005-02-25
MXPA03006686A (es) 2004-05-31
PL363576A1 (en) 2004-11-29
EP1355641B1 (en) 2005-09-21
HU229070B1 (hu) 2013-07-29
RU2257895C2 (ru) 2005-08-10
DE60206245D1 (de) 2006-02-02
PL215109B1 (pl) 2013-10-31
WO2002062330A3 (en) 2003-04-03
CZ20032095A3 (en) 2004-05-12
NO20033273L (no) 2003-07-18
BRPI0206804B1 (pt) 2018-09-25
EE05233B1 (et) 2009-12-15
SK287632B6 (sk) 2011-04-05
ATE304846T1 (de) 2005-10-15
ITMI20010206A1 (it) 2002-08-02
NO334285B1 (no) 2014-01-27
ZA200304861B (en) 2004-06-30
PT1355641E (pt) 2005-11-30
ES2248541T3 (es) 2006-03-16
DK1355641T3 (da) 2005-10-17
CA2432432C (en) 2008-03-25
US7560487B2 (en) 2009-07-14
EP1355641A2 (en) 2003-10-29
CN1561205A (zh) 2005-01-05
DE60206245T2 (de) 2006-06-14
HUP0303024A3 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
US7846971B2 (en) N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them
BR0206804A (pt) Utilização de (r)-ibuprofeno metanossulfonamida e sais do mesmo no tratamento e prevenção de reações de rejeição a órgãos transplantados
BRPI0606435A2 (pt) composições não irritantes que contêm sais de zinco
EA200700860A1 (ru) (бифенил)карбоновые кислоты и их производные
GT199900199A (es) Composiciones de glisofato acuoso altamente concentrado.
BR9915208A (pt) Preparado farmacêutico de moxifloxacina
PT1100805E (pt) Sais de nitrato medicinais
BR0100155A (pt) Azabenzimidazóis aril substituìdos e sua utilização no tratamento de hiv e doenças relacionadas com aids
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
BRPI0507334A (pt) processo para a preparação de -1(2s,3s)-2-benzidril-n-(5-terc-butil-2-metoxibenzila)q uinuclidin-3-amina
BR9908702A (pt) Composto, processos para inibir sìntese de óxido nìtrico em um paciente, para inibir seletivamente sìntese de óxido nìtrico produzido pela no sintase indutìvel no óxido nìtrico produzido pelas formas constitutivas de no sintase em um paciente e para diminuir nìveis de óxido nìtrico em um paciente, e, composição farmacêutica
ATE305777T1 (de) Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation
BR0308316A (pt) Sais de nateglinida
AR035889A1 (es) Citrato de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9- pentaeno y composiciones farmaceuticas que la contienen y su uso para la elaboracion de medicamentos
BR0014895A (pt) Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais
ATE521344T1 (de) Calciumsalze zur behandlung von psoriasis, dermatitis und schuppen
BR0113268A (pt) Uso de sulfonas de triazinotriona para o combate de coccidioses
BR0316751A (pt) Análogos de gabapentina para fibromialgia e outros distúrbios relacionados
BRPI0409441A (pt) sal de amÈnio, composição farmacêutica, e, método para tratamento de um mamìfero sofrendo ou susceptìvel a cáncer
BR0315917A (pt) Utilização do sal distrÈnico do ácido 2-[n,n-di(carboximetil)amino]-3-ciano-4-carboximetil-ti ofeno-5-carboxìlico para a obtenção de medicamentos destinados ao tratamento das dores gastroduodenais
DE59705183D1 (de) Therapeutische mittel, enthaltend ebselen gegen asthma
PL1514545T3 (pl) Zastosowanie tolperyzonu do leczenia skurczów narządów zbudowanych zasadniczo z mięśni gładkich
RU2009112724A (ru) Циклические сульфоны в качестве митохондриальных натрий-кальциевых обменников
ATE464042T1 (de) Verwendung von neboglamine zur behandlung von schizophrenie
BRPI0415455A (pt) processo de administração

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DOMPE PHA.R.MA S.P.A. (IT)

Free format text: TRANSFERIDO DE: DOMPE S.P.A.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: DOMPE' S.P.A. (IT)

Free format text: TRANSFERIDO POR FUSAO DE: DOMPE PHA.R.MA S.P.A.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: DOMPE FARMACEUTICI S.P.A (IT)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2616 DE 23-02-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.